QPPV.COM KNOWLEDGE ASSESSMENT

Missing Information

Test your understanding of the concepts covered by Missing Information.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which governance arrangement best reflects the article's recommended division of responsibilities?

The QPPV manages every operational study task and regulatory affairs approves scientific classifications A safety or risk manager handles day-to-day management, a governance committee approves major decisions, and the QPPV provides system oversight and escalation Only clinical development decides classification, without involvement from PV or regulatory affairs The governance committee identifies all evidence, conducts all analyses and replaces the QPPV

Question 2 of 10 Which document set would provide the strongest inspection-ready traceability for a Missing Information item?

Only the current RMP narrative and the product label The evidence mapping, decision records, linked protocol or PASS documents, interim reports, approvals and version history Only informal email correspondence between study personnel A list of planned activities without owners, timelines or results

Question 3 of 10 Which event could justify reclassification of a Missing Information item to an Important Potential Risk?

The sponsor changes the internal document template New evidence supports a plausible association with a specific serious adverse outcome in the previously under-characterised population The number of governance meetings decreases The product receives a new trade name

Question 4 of 10 Which feature most clearly demonstrates that a planned activity is linked to the Missing Information entry rather than merely listed in the RMP?

The activity has a generic title resembling the RMP section heading The activity specifies the gap it addresses, endpoints, owner, milestones, data sources and decision criteria The activity is conducted by an external organisation The activity has a publication plan but no protocol or reporting timeline

Question 5 of 10 For a rare outcome in a large real-world population, which design principle is most appropriate?

Use an efficient design such as a nested case–control study or self-controlled case series, with prespecified methods Exclude all patients with comorbidities to guarantee comparability Use only spontaneous case counts without a defined denominator Avoid sensitivity analyses because they introduce complexity

Question 6 of 10 A medicine is expected to be used chronically, but the clinical development programme has a median treatment exposure of six months. What is the strongest reason this may represent Missing Information?

The shorter exposure automatically proves a long-term identified risk Long-latency toxicity or other safety effects may not be adequately characterised for the intended duration of use All products with a median exposure below one year require a PASS Short-term studies are never relevant to chronic treatment

Question 7 of 10 Which action is generally most proportionate when a relevant knowledge gap has limited potential to change clinical use but can still be monitored through routine systems?

Immediate contraindication for the entire population Routine pharmacovigilance with specified monitoring or targeted analyses Automatic withdrawal of the product A mandatory interventional trial in every patient

Question 8 of 10 When might risk minimisation be considered in relation to Missing Information?

Whenever any subgroup has fewer than 100 exposed patients Rarely as a measure driven solely by missing data, but potentially when the uncertainty has immediate safety implications Only after the item has been removed from the RMP Never, because risk minimisation applies only to identified risks

Question 9 of 10 Why are predefined removal or reclassification criteria important for Missing Information items?

They ensure that items remain in the RMP indefinitely They provide objective, transparent standards for determining whether new evidence has adequately addressed the uncertainty They eliminate the need for governance approval They allow any single study result to determine the outcome automatically

Question 10 of 10 A product is expected to be used with a specific interacting medicine, but no safety data exist for the combination and pharmacodynamic interaction is plausible. What should the sponsor assess first?

Whether the combination is clinically expected and whether the information gap could alter dosing, monitoring, labelling or benefit–risk assessment Whether the interacting medicine has the same marketing authorisation holder Whether the combination appears in the product's brand name Whether all patients in the pivotal trials received combination therapy

Missing Information

Cookie Settings